SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quants sharp rally is being linked by traders to its Oracle integration and reported role in The Clearing Houses tokenized-deposit infrastructure, alongside expectations that limited token supply could amplify demand. Bullish speculation about bank adoption and a short squeeze is tempered by debate over whether these partnerships will create meaningful demand for QNT itself, as well as concern about the rallys volatility.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors 24-month HOPE-3 extension data showing slower upper-limb decline after patients switched to deramiocel is driving attention, with traders viewing it as support for the drugs FDA application. Many are optimistic about approval, while others question how regulators will weigh the analysis and the disputed statistical plan; approval remains uncertain.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances raised 2026 revenue outlook, reflecting stronger demand for its cancer therapies, is driving a sharp rally and analyst upgrades. Many traders view the move as validation of the commercial ramp and anticipate further pipeline catalysts, while others caution about overbought conditions and debate whether short covering is amplifying the gains.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

The selloff is being linked to competition from Kalshi and Polymarket and concerns that DraftKings investment in its own prediction-market business will pressure margins. Traders disagree over whether growing DKeX activity and legal challenges to rivals will offset those risks, while many react to the stocks steep decline with frustration.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

A judges pause of the broader cannabis Schedule I-to-III rescheduling case, while considering whether to add a GAO report on agency procedures, has delayed a closely watched catalyst for MSOS and pressured the sector. Traders are split between viewing the stay as a procedural delay that leaves the rescheduling thesis intact and fearing a prolonged setback; the earlier medical-cannabis move to Schedule III was not reversed.

Fair Isaac Corp. engages in the provision of decision management solutions. It operates through the Software and Scores segments. The Software segment includes pre-configured analytic and decision management solutions designed for a specific type of business need or process. The Scores segment focuses on business-to-business scoring solutions and services, business-to-consumer scoring solutions and services including myFICO solutions for consumers and associated professional services. The company was founded by Bill Fair and Earl Isaac in 1956 and is headquartered in San Jose, CA.

Fair Isaac Corp.

Fair, Isaac Corp.

FHFAs move to include VantageScore alongside FICO in Fannie Mae and Freddie Mac mortgage pricingand Rocket Mortgages planned preference for VantageScore on eligible loanshas raised concerns that competition could erode FICOs mortgage-scoring dominance and pricing power. Traders are sharply divided between expecting further repricing and viewing the selloff as an overreaction, noting that adoption is not universal and FICO remains widely used.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desks steep selloff is being tied to slowing growth and weak revenue guidance, with traders also debating whether competition from Amazon and AIand a reported Safari ad-serving issuecould pressure its ad business further. Bearish posts criticize management and fear more downside, while bulls point to the companys cash and cash flow and argue the shares may be oversold.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vandas Phase III trial of HETLIOZ for delayed sleep-wake phase disorder met its primary endpoint, prompting discussion of a potential label expansion and an FDA meeting before a planned supplemental application. Traders welcomed the readout and speculated about commercial upside or a buyout, while some cautioned that the study was small and approval is not yet assured.

PENGU is the official coin of Pudgy Penguins.  Pudgy Penguins has become the face of crypto with one of the most influential communities in the industry. From large companies wearing the Penguin, to being featured in ETF commercials, to garnering millions of followers and over 100 billion views, the Pengu has become a cultural icon making PENGU the world’s social currency.  PENGU allows for the ever-expanding Pudgy Penguin fanbase and the hundreds of millions of people outside of crypto that see and share the Pudgy Penguin everyday, to join The Huddle. PENGU is a symbol for community, memes, and good vibes.  Believe in Pengu. Believe in the Prophecy.

Pudgy Penguins

A rebound in PENGU has renewed momentum-focused discussion, with bullish traders anticipating a breakout while others warn that rallies have repeatedly faded. A claim that Luca Netz wants to take Pudgy Penguins public and link token and NFT holders is circulating, but it is not broadly corroborated in the discussion.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

Attention centers on MoonLakes anticipated HS BLA submission for sonelokimab, with traders watching for filing and FDA-review updates. Optimists see the filing as a potential catalyst, while skepticism about the drugs differentiation after IZAR-1, the recent dilution, and managements commercialization strategy has fueled bearish sentiment and debate over a possible partnership or buyout.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


CounselorShell

Michelle L Neumann